Artiva’s mission is to deliver highly effective cellular immunotherapies that are also safe and immediately accessible to cancer patients. Artiva’s pipeline of universal and targeted NK cell therapies leverages the innate anti-tumor biology and safety features of NK cells. The therapies are optimized for enhanced efficacy through chimeric antigen receptors (CARs) or therapeutic antibody combinations. Artiva’s pipeline is built on a manufacturing platform that supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies and proprietary CAR-NK technologies to augment therapeutic activity. Artiva’s platform incorporates cell expansion, activation, and engineering technology developed by the company’s corporate partner, GC LabCell, a member of the GC family of companies, one of the Republic of Korea’s leading biopharmaceutical groups.